NCT00082316
Completed
Phase 2
A Randomized, Open-Label Study of the Tolerability of Three Local Anesthetic Formulations in Conjunction With NGX-4010 for the Treatment of Neuropathic Pain
NeurogesX1 site in 1 countryMay 7, 2004
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Herpes Zoster
- Sponsor
- NeurogesX
- Locations
- 1
- Status
- Completed
- Last Updated
- 18 years ago
Overview
Brief Summary
This study is a randomized, open-label multi-center evaluation of the tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of one of three 4% lidocaine-based local anesthetic products. Eligible subjects will have moderate to severe neuropathic pain secondary to painful diabetic neuropathy (PDN), postherpetic neuralgia (PHN) or HIV-associated neuropathy (HIV-AN), with average numeric pain rating scale (NPRS) scores during screening of 3 to 8 (inclusive).
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Withdrawn
Phase 2
Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus ViremiaAdenovirusNCT03532035Chimerix
Completed
Phase 3
Tolerability of Rebif® Injection With and Without the Use of Rebiject™Mini in Relapsing-Remitting Multiple Sclerosis SubjectsMultiple Sclerosis, Relapsing-remittingNCT00292253EMD Serono1,883
Unknown
Not Applicable
EnergieShake® Acceptability and Tolerance StudyMalnutritionNCT02788032Anaiah Healthcare Pvt Ltd18
Unknown
Not Applicable
EnergieShake 1.5kcal Complete Acceptability and Tolerance StudyMalnutritionNCT02796482Anaiah Healthcare Pvt Ltd18
Terminated
Not Applicable
Tolerability, Safety and Efficacy of a New Frequency of Vibrant Capsule AdministrationConstipationNCT02829047Vibrant Ltd.25